These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
326 related articles for article (PubMed ID: 10734292)
1. Quantitation of primitive and lineage-committed progenitors in mobilized peripheral blood for prediction of platelet recovery post autologous transplant. Hogge DE; Lambie K; Sutherland HJ; Benny WB; Dalal B; Currie C; Barnett MJ; Eaves AC; Eaves CJ Bone Marrow Transplant; 2000 Mar; 25(6):589-98. PubMed ID: 10734292 [TBL] [Abstract][Full Text] [Related]
2. Factors affecting hemopoietic recovery after high-dose therapy and autologous peripheral blood progenitor cell transplantation: a single center experience. Olivieri A; Offidani M; Montanari M; Ciniero L; Cantori I; Ombrosi L; Masia CM; Centurioni R; Mancini S; Brunori M; Leoni P Haematologica; 1998 Apr; 83(4):329-37. PubMed ID: 9592983 [TBL] [Abstract][Full Text] [Related]
3. Changes in endogenous TPO levels during mobilization chemotherapy are predictive of CD34+ megakaryocyte progenitor yield and identify patients at risk of delayed platelet engraftment post-PBPC transplant. Maharaj D; Steinberg JP; Gouvea JV; Gieser PW Bone Marrow Transplant; 1999 Mar; 23(6):539-48. PubMed ID: 10217183 [TBL] [Abstract][Full Text] [Related]
4. Randomized comparison of granulocyte colony-stimulating factor versus granulocyte-macrophage colony-stimulating factor plus intensive chemotherapy for peripheral blood stem cell mobilization and autologous transplantation in multiple myeloma. Arora M; Burns LJ; Barker JN; Miller JS; Defor TE; Olujohungbe AB; Weisdorf DJ Biol Blood Marrow Transplant; 2004 Jun; 10(6):395-404. PubMed ID: 15148493 [TBL] [Abstract][Full Text] [Related]
5. Peripheral blood progenitor cell mobilization with intermediate-dose cyclophosphamide, sequential granulocyte-macrophage-colony-stimulating factor and granulocyte-colony-stimulating factor, and scheduled commencement of leukapheresis in 225 patients undergoing autologous transplantation. Bashey A; Donohue M; Liu L; Medina B; Corringham S; Ihasz A; Carrier E; Castro JE; Holman PR; Xu R; Law P; Ball ED; Lane TA Transfusion; 2007 Nov; 47(11):2153-60. PubMed ID: 17958545 [TBL] [Abstract][Full Text] [Related]
6. Mobilization of peripheral blood stem cells following myelosuppressive chemotherapy: a randomized comparison of filgrastim, sargramostim, or sequential sargramostim and filgrastim. Weaver CH; Schulman KA; Buckner CD Bone Marrow Transplant; 2001 May; 27 Suppl 2():S23-9. PubMed ID: 11436117 [TBL] [Abstract][Full Text] [Related]
7. Correlation of colony-forming cells, long-term culture initiating cells and CD34+ cells in apheresis products from patients mobilized for peripheral blood progenitors with different regimens. Bender JG; Lum L; Unverzagt KL; Lee W; Van Epps D; George S; Coon J; Ghalie R; McLeod B; Kaizer H Bone Marrow Transplant; 1994 Apr; 13(4):479-85. PubMed ID: 7517260 [TBL] [Abstract][Full Text] [Related]
8. Very large amounts of peripheral blood progenitor cells eliminate severe thrombocytopenia after high-dose melphalan in advanced breast cancer patients. Benedetti G; Patoia L; Giglietti A; Alessio M; Pelicci P; Grignani F Bone Marrow Transplant; 1999 Nov; 24(9):971-9. PubMed ID: 10556956 [TBL] [Abstract][Full Text] [Related]
9. Peripheral blood progenitor cell collections in cancer patients: analysis of factors affecting the yields. Sautois B; Fraipont V; Baudoux E; Fassotte MF; Hermanne JP; Jérusalem G; Bours V; Bosquée L; Schaaf-Lafontaine N; Paulus JM; Sondag D; Fillet G; Beguin Y Haematologica; 1999 Apr; 84(4):342-9. PubMed ID: 10190949 [TBL] [Abstract][Full Text] [Related]
10. Subsets of CD34+ hematopoietic progenitors and platelet recovery after high dose chemotherapy and peripheral blood stem cell transplantation. Meldgaard Knudsen L; Jensen L; Jarlbaek L; Hansen PG; Hansen SW; Drivsholm L; Nikolaisen K; Gaarsdal E; Johnsen HE Haematologica; 1999 Jun; 84(6):517-24. PubMed ID: 10366795 [TBL] [Abstract][Full Text] [Related]
11. Peripheral blood stem cell mobilization by granulocyte colony-stimulating factor alone and engraftment kinetics following autologous transplantation in children and adolescents with solid tumor. Watanabe H; Watanabe T; Suzuya H; Wakata Y; Kaneko M; Onishi T; Okamoto Y; Abe T; Kawano Y; Kagami S; Takaue Y Bone Marrow Transplant; 2006 Apr; 37(7):661-8. PubMed ID: 16489358 [TBL] [Abstract][Full Text] [Related]
12. Characterization and quantitation of primitive hematopoietic progenitor cells present in peripheral blood autografts. Tong J; Hoffman R; Siena S; Srour EF; Bregni M; Gianni AM Exp Hematol; 1994 Sep; 22(10):1016-24. PubMed ID: 8088376 [TBL] [Abstract][Full Text] [Related]
13. Failure to achieve a threshold dose of CD34+CD110+ progenitor cells in the graft predicts delayed platelet engraftment after autologous stem cell transplantation for multiple myeloma. Wallington-Beddoe CT; Gottlieb DJ; Garvin F; Antonenas V; Sartor MM Biol Blood Marrow Transplant; 2009 Nov; 15(11):1386-93. PubMed ID: 19822297 [TBL] [Abstract][Full Text] [Related]
14. Relationship of CD34+ cell dose to early and late hematopoiesis following autologous peripheral blood stem cell transplantation. Kiss JE; Rybka WB; Winkelstein A; deMagalhaes-Silverman M; Lister J; D'Andrea P; Ball ED Bone Marrow Transplant; 1997 Feb; 19(4):303-10. PubMed ID: 9051238 [TBL] [Abstract][Full Text] [Related]
15. CD34+ selection of hematopoietic blood cell collections and autotransplantation in lymphoma: overnight storage of cells at 4 degrees C does not affect outcome. Lazarus HM; Pecora AL; Shea TC; Koç ON; White JM; Gabriel DA; Cooper BW; Gerson SL; Krieger M; Sing AP Bone Marrow Transplant; 2000 Mar; 25(5):559-66. PubMed ID: 10713636 [TBL] [Abstract][Full Text] [Related]
16. Progenitor content of autologous grafts: mobilized bone marrow vs mobilized blood. Dahl E; Burroughs J; DeFor T; Verfaillie C; Weisdorf D Bone Marrow Transplant; 2003 Sep; 32(6):575-80. PubMed ID: 12953129 [TBL] [Abstract][Full Text] [Related]
17. A randomized trial of granulocyte colony-stimulating factor (Neupogen) starting day 1 vs day 7 post-autologous stem cell transplantation. Bence-Bruckler I; Bredeson C; Atkins H; McDiarmid S; Hamelin L; Hopkins H; Perry G; Genest P; Huebsch L Bone Marrow Transplant; 1998 Nov; 22(10):965-9. PubMed ID: 9849693 [TBL] [Abstract][Full Text] [Related]
18. Stem cell function and engraftment is not affected by "in vivo purging" with rituximab for autologous stem cell treatment for patients with low-grade non-Hodgkin's lymphoma. Buckstein R; Imrie K; Spaner D; Potichnyj A; Robinson JB; Nanji S; Pennel N; Reis M; Pinkerton P; Dubé I; Hewitt K; Berinstein NL Semin Oncol; 1999 Oct; 26(5 Suppl 14):115-22. PubMed ID: 10561026 [TBL] [Abstract][Full Text] [Related]
19. The importance of CD34+/CD33- cells in platelet engraftment after intensive therapy for cancer patients given peripheral blood stem cell rescue. Millar BC; Millar JL; Shepherd V; Blackwell P; Porter H; Cunningham D; Judson I; Treleaven J; Powles RL; Catovsky D Bone Marrow Transplant; 1998 Sep; 22(5):469-75. PubMed ID: 9733270 [TBL] [Abstract][Full Text] [Related]
20. Mobilization of hematopoietic progenitor cells with paclitaxel (taxol) as a single chemotheraupetic agent, associated with rhG-CSF. Gómez-Espuch J; Moraleda JM; Ortuño F; Lozano ML; Ayala F; Vallejo C; de Arriba F; Vicente V Bone Marrow Transplant; 2000 Feb; 25(3):231-5. PubMed ID: 10673692 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]